Univercells SA, a Gosselies, Belgium-based company that designs single-use cost-efficient bioprocess solutions, closed a €3m equity investment.
Takeda Pharmaceutical Company Limited made the investment through its strategic venture arm Takeda Ventures.
The two companies will launch a development program to integrate Univercells’ continuous integrated manufacturing methods into the Takeda vaccines production platform.
Founded in 2013 by CEO Hugues Bultot and CTO Jose Castillo, Univercells leverages manufacturing sciences to design single-use bioprocess solutions to make biologics available and affordable for all. It creates value for manufacturers and healthcare systems by allowing them to develop local bioproduction facilities, including those for biosimilars. These production units are less costly to build and to operate, while offering flexible capabilities, from small to large batches.